SCHEMBL14938263

SCHEMBL14938263

Cn1ncc(I)c1-c1cnn(-c2ccc(C(F)(F)F)cc2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 1/20 0.43
FLT3 P36888 1/20 0.43
GRM4 Q14833 2/20 0.40
MELK Q14680 3/20 0.38
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
NOTUM Q6P988 1/20 0.35
KCNH2 Q12809 1/20 0.35
PTGS2 P35354 1/20 0.35
EPHX2 P34913 1/20 0.35
PDE2A O00408 7/20 0.34
SRC P12931 1/20 0.33
BRAF P15056 1/20 0.33
KDR P35968 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
CYP1A2 P05177 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14937840 0.85 GRM4 (0.46) GRM4MELKKCNH2
SCHEMBL14937981 0.83 PDE2A (0.44) KCNH2PDE2AKDM4EALDH1A1LMNA
SCHEMBL14938007 0.82 MAP4K4 (0.46) GRM4MELKMEN1NPC1RAB9A
SCHEMBL14973156 0.80 MEN1 (0.45) NTRK1FLT3GRM4MELKMEN1
SCHEMBL14938051 0.80 MAPKAPK2 (0.50) GRM4MELKMEN1NPC1RAB9A
SCHEMBL14938162 0.76 NTRK1 (0.45) NTRK1FLT3GRM4MELKMEN1
SCHEMBL14973016 0.75 MAPT (0.46) NTRK1FLT3MEN1NPC1RAB9A
SCHEMBL19120855 0.74 NOTUM (0.44) NTRK1FLT3GRM4MEN1NPC1
SCHEMBL14938131 0.72 KCNH2 (0.44) NPC1RAB9ANOTUMKCNH2KDR
SCHEMBL14937664 0.71 PTGS2 (0.46) NTRK1FLT3MELKPTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8642626-B2 Ethinyl-pyrazole derivative TAISHO PHARMACEUTICAL CO., LTD. (JP) 2014-02-04 US disclosed
EP-2604602-A1 HETEROARYL-PYRAZOLE DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2013-06-19 EP disclosed
EP-2599775-A1 ETHINYL-PYRAZOLE DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2013-06-05 EP disclosed
US-20130137865-A1 HETEROARYL-PYRAZOLE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2013-05-30 US disclosed
US-20130123500-A1 ETHINYL-PYRAZOLE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD (JP) 2013-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130137865-A1 HETEROARYL-PYRAZOLE DERIVATIVE GRIN2C, GRIN2B, GRIN3A NTRK1 1812/4885FLT3 3055/4885GRM4 18/4885
US-20130123500-A1 ETHINYL-PYRAZOLE DERIVATIVE GABRE, GRIN3A, GRIK5 NTRK1 2216/4885FLT3 2592/4885GRM4 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.